PF 6263276

Drug Profile

PF 6263276

Alternative Names: PF-06263276; PF-6263276

Latest Information Update: 12 May 2015

Price : $50

At a glance

  • Originator Pfizer
  • Class Antipsoriatics
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Plaque psoriasis

Most Recent Events

  • 27 Feb 2015 Discontinued - Phase-I for Plaque psoriasis in Germany (Topical)
  • 27 Feb 2015 Discontinued - Phase-I for Plaque psoriasis (In volunteers) in Belgium (Topical)
  • 01 Feb 2015 Pfizer completes a phase I trial in Plaque psoriasis in Germany (NCT02193815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top